Monthly
US$200
Billed every month
Tropicamide Phenylephrine Eye Drops(复方托吡卡胺滴眼液)
Companies, stages and changes, with each record available on this page.
Last 90 days: Marketing application approved: 2 applicationsAccepted: 3 applications
Current coverage may be incomplete
Which companies are listed, and at what stages?
Each source is counted separately. Expand a list to inspect companies, identifiers, dates and sources.
Company names, approval identifiers and strengths are retained as recorded in the Chinese sources. Category labels include the original wording for verification.
Catalogue holders1View records ↓
Under-review filings8View records ↓
This year’s generic filers5View records ↓
NHSA approval numbers17View records ↓
API companies with A status0View records ↓
Chemical-drug catalogue
Loaded records: 1 holders; 0 in the quality-and-efficacy consistency-evaluation category, and 0 in the new chemical-registration-classification generic category. Category counts may overlap.
| Marketing authorization holder | Manufacturer | Approval number | Approved | Strength / specification | Catalogue category (source text) | View source |
|---|---|---|---|---|---|---|
| Santen Pharmaceutical Co.,Ltd. | Santen Pharmaceutical Co.,Ltd.Shiga Plant | H20171350 | 1989/01/31 | 1ml:托吡卡胺5mg与盐酸去氧肾上腺素5mg | Imported originator drug (进口原研药品) | CDE |
Distinct full holder names; manufacturers are used only where the holder is unstated. The catalogue covers only part of the chemical-drug market. Categories are counted as recorded, not as a complete market census.
NHSA drug codes
Loaded records: 17 distinct approval numbers and 14 companies.
| Company / applicant | Approval number | Strength / specification | NHSA class | NHSA drug code | View source |
|---|---|---|---|---|---|
| 广东众生药业股份有限公司 | 国药准字H20254637 | 10ml:托吡卡胺50mg与盐酸去氧肾上腺素50mg | Category B (乙) | XS01FAF508G010010100371 | NHSA |
| 沈阳兴齐眼药股份有限公司 | 国药准字H20055546 | 5ml:托吡卡胺25mg,盐酸去氧肾上腺素25mg | Category B (乙) | XS01FAF508G010010101322 | NHSA |
| 苏州乐珠制药有限公司 | 国药准字H20253480 | 10ml∶托吡卡胺50mg与盐酸去氧肾上腺素50mg | Category B (乙) | XS01FAF508G010010101652 | NHSA |
| 湖北远大天天明制药有限公司 | 国药准字H20253245 | 0.4ml:托吡卡胺2mg与盐酸去氧肾上腺素2mg | Category B (乙) | XS01FAF508G010010101967 | NHSA |
| 邯郸奥维生物科技有限公司 | 国药准字H20044926 | 5ml:托吡卡胺25mg和盐酸去氧肾上腺素25mg | Category B (乙) | XS01FAF508G010010102585 | NHSA |
| 石家庄格瑞药业有限公司 | 国药准字H20256047 | 10ml:托吡卡胺50mg与盐酸去氧肾上腺素50mg | Category B (乙) | XS01FAF508G010010102733 | NHSA |
| 津药永光(河北)制药有限公司 | 国药准字H20066782 | 5ml:托吡卡胺25mg,盐酸去氧肾上腺素25mg | Category B (乙) | XS01FAF508G010010102817 | NHSA |
| 长春迪瑞制药有限公司 | 国药准字H20103127 | 5ml:托吡卡胺25mg、盐酸去氧肾上腺素25mg | Category B (乙) | XS01FAF508G010010103305 | NHSA |
| Santen Pharmaceutical Co., Ltd. | 国药准字J20180051 | 1ml:托吡卡胺5mg与盐酸去氧肾上腺素5mg | Category B (乙) | XS01FAF508G010010109591 | NHSA |
| Santen Pharmaceutical Co.,Ltd. | 国药准字HJ20171349 | 1ml:托吡卡胺5mg与盐酸去氧肾上腺素5mg | Category B (乙) | XS01FAF508G010010178986 | NHSA |
| 四川禾亿制药有限公司 | 国药准字H20253368 | 0.4ml∶托吡卡胺2mg与盐酸去氧肾上腺素2mg | Category B (乙) | XS01FAF508G010010181567 | NHSA |
| 南京恒道医药科技股份有限公司 | 国药准字H20249621 | 0.4ml: 托吡卡胺2mg与盐酸去氧肾上腺素2mg | Category B (乙) | XS01FAF508G010010183035 | NHSA |
| 山东辰欣佛都药业股份有限公司 | 国药准字H20254580 | 10ml:托吡卡胺50mg与盐酸去氧肾上腺素50mg | Category B (乙) | XS01FAF508G010010183191 | NHSA |
| 苏州欧康维视生物科技有限公司 | 国药准字H20255223 | 0.4ml:托吡卡胺2mg与盐酸去氧肾上腺素2mg | Category B (乙) | XS01FAF508G010010183562 | NHSA |
| 汇禹远和(海南)药业有限公司 | 国药准字H20234730 | 0.4ml:托吡卡胺2mg与盐酸去 氧肾上腺素2mg | Category B (乙) | XS01FAF508G010010183867 | NHSA |
| 湖北远大天天明制药有限公司 | 国药准字H20253245 | 0.4ml:托吡卡胺2mg与盐酸去氧肾上腺素2mg | Category B (乙) | XS01FAF508G010010201967 | NHSA |
| 长春迪瑞制药有限公司 | 国药准字H20103127 | 5ml:托吡卡胺25mg、盐酸去氧肾上腺素25mg | Category B (乙) | XS01FAF508G010010203305 | NHSA |
| 四川禾亿制药有限公司 | 国药准字H20253368 | 0.4ml∶托吡卡胺2mg与盐酸去氧肾上腺素2mg | Category B (乙) | XS01FAF508G010010281567 | NHSA |
| 南京恒道医药科技股份有限公司 | 国药准字H20249621 | 0.4ml: 托吡卡胺2mg与盐酸去氧肾上腺素2mg | Category B (乙) | XS01FAF508G010010283035 | NHSA |
| 山东辰欣佛都药业股份有限公司 | 国药准字H20254580 | 10ml:托吡卡胺50mg与盐酸去氧肾上腺素50mg | Category B (乙) | XS01FAF508G010010283191 | NHSA |
| 湖北远大天天明制药有限公司 | 国药准字H20253245 | 0.4ml:托吡卡胺2mg与盐酸去氧肾上腺素2mg | Category B (乙) | XS01FAF508G010010301967 | NHSA |
| 四川禾亿制药有限公司 | 国药准字H20253368 | 0.4ml∶托吡卡胺2mg与盐酸去氧肾上腺素2mg | Category B (乙) | XS01FAF508G010010381567 | NHSA |
| 山东辰欣佛都药业股份有限公司 | 国药准字H20254580 | 10ml:托吡卡胺50mg与盐酸去氧肾上腺素50mg | Category B (乙) | XS01FAF508G010010383191 | NHSA |
| 湖北远大天天明制药有限公司 | 国药准字H20253245 | 0.4ml:托吡卡胺2mg与盐酸去氧肾上腺素2mg | Category B (乙) | XS01FAF508G010010401967 | NHSA |
| 四川禾亿制药有限公司 | 国药准字H20253368 | 0.4ml∶托吡卡胺2mg与盐酸去氧肾上腺素2mg | Category B (乙) | XS01FAF508G010010481567 | NHSA |
| 山东辰欣佛都药业股份有限公司 | 国药准字H20254580 | 10ml:托吡卡胺50mg与盐酸去氧肾上腺素50mg | Category B (乙) | XS01FAF508G010010483191 | NHSA |
| 四川禾亿制药有限公司 | 国药准字H20253368 | 0.4ml∶托吡卡胺2mg与盐酸去氧肾上腺素2mg | Category B (乙) | XS01FAF508G010010581567 | NHSA |
| 山东辰欣佛都药业股份有限公司 | 国药准字H20254580 | 10ml:托吡卡胺50mg与盐酸去氧肾上腺素50mg | Category B (乙) | XS01FAF508G010010583191 | NHSA |
| 四川禾亿制药有限公司 | 国药准字H20253368 | 0.4ml∶托吡卡胺2mg与盐酸去氧肾上腺素2mg | Category B (乙) | XS01FAF508G010010681567 | NHSA |
| 山东辰欣佛都药业股份有限公司 | 国药准字H20254580 | 10ml:托吡卡胺50mg与盐酸去氧肾上腺素50mg | Category B (乙) | XS01FAF508G010010683191 | NHSA |
| 山东辰欣佛都药业股份有限公司 | 国药准字H20254580 | 10ml:托吡卡胺50mg与盐酸去氧肾上腺素50mg | Category B (乙) | XS01FAF508G010010783191 | NHSA |
| 沈阳兴齐眼药股份有限公司 | 国药准字H20123453 | 1ml:托吡卡胺5mg,盐酸去氧肾上腺素5mg | Category B (乙) | XS01FAF508G010020101322 | NHSA |
| 邯郸奥维生物科技有限公司 | 国药准字H20044926 | 5ml:托吡卡胺25mg和盐酸去氧肾上腺素25mg | Category B (乙) | XS01FAF508G010020102585 | NHSA |
| 石家庄格瑞药业有限公司 | 国药准字H20256046 | 0.4ml: 托吡卡胺2mg与盐酸去氧肾上腺素2mg | Category B (乙) | XS01FAF508G010020102733 | NHSA |
| 石家庄格瑞药业有限公司 | 国药准字H20256046 | 0.4ml: 托吡卡胺2mg与盐酸去氧肾上腺素2mg | Category B (乙) | XS01FAF508G010020202733 | NHSA |
| 石家庄格瑞药业有限公司 | 国药准字H20256046 | 0.4ml: 托吡卡胺2mg与盐酸去氧肾上腺素2mg | Category B (乙) | XS01FAF508G010020302733 | NHSA |
| 石家庄格瑞药业有限公司 | 国药准字H20256046 | 0.4ml: 托吡卡胺2mg与盐酸去氧肾上腺素2mg | Category B (乙) | XS01FAF508G010020402733 | NHSA |
Approval numbers and companies are deduplicated separately; packaging records remain individually listed. An empty insurance class means it is unstated. NHSA codes supply no approval date and do not establish the outcome of an acceptance number.
Current under-review applications
Loaded records: 8 filings and 7 distinct first applicants.
Import re-registration 2 · Generic 6
| Company / applicant | Acceptance number | Application type | Accepted | Strength / specification | View source |
|---|---|---|---|---|---|
| Santen Pharmaceutical Co. Ltd.;Santen Pharmaceutical Co. Ltd. Shiga Plant | JYHZ2600201 | Import re-registration | 2026/08/21 | Not stated by source | CDE |
| Santen Pharmaceutical Co. Ltd.;Santen Pharmaceutical Co. Ltd. Shiga Plant | JYHZ2600200 | Import re-registration | 2026/08/21 | Not stated by source | CDE |
| 湖南迈欧医疗科技有限公司 | CYHS2601878 | Generic | 2026/08/03 | Not stated by source | CDE |
| 润尔眼科药物（广州）有限公司 | CYHS2601785 | Generic | 2026/07/27 | Not stated by source | CDE |
| 北京汇恩兰德制药股份有限公司 | CYHS2601510 | Generic | 2026/06/26 | Not stated by source | CDE |
| 珠海前列药业有限公司;湖南华纳大药厂股份有限公司 | CYHS2600613 | Generic | 2026/03/05 | Not stated by source | CDE |
| 成都普什制药有限公司 | CYHS2503545 | Generic | 2025/09/28 | Not stated by source | CDE |
| 武汉五景药业有限公司 | CYHS2602626 | Generic | 2026/10/26 | Not stated by source | CDE |
New generic filings in 2026
Loaded records: 5 filings and 5 distinct first applicants.
| Company / applicant | Acceptance number | Application type | Accepted | Strength / specification | View source |
|---|---|---|---|---|---|
| 湖南迈欧医疗科技有限公司 | CYHS2601878 | Generic | 2026/08/03 | Not stated by source | CDE |
| 润尔眼科药物（广州）有限公司 | CYHS2601785 | Generic | 2026/07/27 | Not stated by source | CDE |
| 北京汇恩兰德制药股份有限公司 | CYHS2601510 | Generic | 2026/06/26 | Not stated by source | CDE |
| 珠海前列药业有限公司;湖南华纳大药厂股份有限公司 | CYHS2600613 | Generic | 2026/03/05 | Not stated by source | CDE |
| 武汉五景药业有限公司 | CYHS2602626 | Generic | 2026/10/26 | Not stated by source | CDE |
API registrations
Non-component matches: 0 companies with A status and 0 I-status records. Component matches are listed separately and excluded from these counts.
| Name | Company / applicant | Registration number | Status | Name match | Source update date | View source |
|---|---|---|---|---|---|---|
| No matching records were found in the currently loaded source data; coverage dates are listed below. | ||||||
A/I are source statuses. Matching uses exact ingredients, salt-normalized names and maintained combination components, without fuzzy matching. A-status companies are deduplicated by the first registered company. Components are excluded from headline counts; the register does not identify the associated formulation.
What changed recently?
Last 90 days, ordered by fact date. Marketing approvals, trial registrations, supplements, notices and review changes are labelled separately.
Trial registration does not mean an application will follow.
This product is outside the trial-registration backfill scope. New registrations after daily collection started remain in scope. Historical rows may also be found by another product search; neither implies complete historical coverage for this product.
NHSA edition maintained to 2026-10-23; latest successful catalogue check: 2026/11/10 07:23. NHSA records lack approval dates; only an earlier edition or observation establishes precedence.
-
2026/11/03Marketing application approved
浙江莎普爱思药业股份有限公司
CYHS2502045 · 国药准字H20266471
Fact date: 2026/11/03 · Publication date: 2026/11/05 · Site observation date: 2026/11/06
The loaded NHSA codes and chemical-drug catalogue contain no evidence confirming an earlier same-name approval for this company. This does not establish the absence of an earlier approval.
View source · Table row 81 ↗ -
2026/11/03Marketing application approved
石家庄四药有限公司
CYHS2501683 · 国药准字H20266468
Fact date: 2026/11/03 · Publication date: 2026/11/05 · Site observation date: 2026/11/06
The loaded NHSA codes and chemical-drug catalogue contain no evidence confirming an earlier same-name approval for this company. This does not establish the absence of an earlier approval.
View source · Table row 68 ↗ -
2026/10/26Accepted
-
2026/08/21Accepted
Santen Pharmaceutical Co. Ltd.;Santen Pharmaceutical Co. Ltd. Shiga Plant
JYHZ2600201
Fact date: 2026/08/21 · Site observation date: 2026/10/22
View source ↗ -
2026/08/21Accepted
Santen Pharmaceutical Co. Ltd.;Santen Pharmaceutical Co. Ltd. Shiga Plant
JYHZ2600200
Fact date: 2026/08/21 · Site observation date: 2026/10/22
View source ↗
How current is each source?
- CDE acceptances and review
- Last successful update: 2026/11/10 07:27
- Chemical-drug catalogue
- Last successful update: 2026/11/10 07:23
Distinct full holder names; manufacturers are used only where the holder is unstated. The catalogue covers only part of the chemical-drug market. Categories are counted as recorded, not as a complete market census.
- Full API register
- Last successful update: 2026/11/10 07:25
- NHSA drug codes
- Last successful update: 2026/11/05 06:45
The fully loaded edition was maintained to 2026-10-23. Publication lags maintenance: the verified 2026-10-16 edition was published on 10-28, a 12-day gap. This is not a fixed lag for every edition.
- NMPA drug delivery notices
- Last successful update: 2026/11/10 18:31
First index-page publication dates: 2026-10-26 to 2026-11-10; 0 pages pending. Covers loaded notices only, not a complete historical approval database.
- Drug Clinical Trial Registry and Information Disclosure Platform
- Last successful update: 2026/11/10 08:10 · Current coverage may be incomplete
Daily collection reads new registrations. Backfill covers registration numbers from 2025 onward (CTR2025/CTR2026), not first-publication years. States are dated observations; revisions are not tracked.
This product is outside the trial-registration backfill scope. New registrations after daily collection started remain in scope. Historical rows may also be found by another product search; neither implies complete historical coverage for this product.
Public-product searches scanned: 3/30; discovered pending details: 20. Record counts in unscanned portions remain unknown.
Filings are counted by acceptance number and filing companies by first applicant. Strengths may have separate applications. Drug names are normalized only for width and whitespace; distinct generic names, dosage forms and combinations remain separate. Unstated strengths are marked. Company counts from different sources must not be added together.
Fact dates are approval dates, acceptance dates, trial first-publication dates or complete-snapshot observation dates, as applicable. Publication and site-observation dates are separate. Historical backfills are not current-period new events. Exit records cover currently inactive applications with an identifiable complete snapshot, not a full review history.
Free follow
Follow changes to Tropicamide Phenylephrine Eye Drops
Up to 3 drugs per email address, in one weekly digest. Starts after email confirmation; unsubscribe at any time.
Subscriptions
Next-day facts and deliverable timelines
- One email the next day when new facts are collected for your followed products.
- Export the complete loaded event timeline for each followed product as CSV.
- Add up to 4 additional recipients, each confirmed by email.
- Increase your follow limit from 3 to 10 products.
Quarterly
US$540
Billed every three months
US$180 per month
Yearly
US$1,920
Billed every year
US$160 per month
Online subscriptions are not enabled. The form below registers interest; it does not charge or activate access.
Separate one-time purchase
US Orange Book × China records comparison
Full table and CSV export for 12 months from payment, with monthly data updates. No automatic renewal.
Subscriptions and comparison-table access are purchased separately. Neither includes the other.
US$490
One payment · 12 months of access
Online comparison-table purchase is not enabled.
Billed by Creem, our merchant of record · Terms · Refund policy